Cephalalgia

1. AILANI J, Lalla A, Halker Singh RB, Holle-Lee D, et al
   Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene-related peptide monoclonal antibodies.
   Cephalalgia. 2024;44:3331024241299377.
   

   >> Share

   
   
2. PULEDDA F, de Boer I, Messina R, Garcia-Azorin D, et al
   Worldwide availability of medications for migraine and tension-type headache: A survey of the International Headache Society.
   Cephalalgia. 2024;44:3331024241297688.
   

   >> Share

   
   
3. YANG C, Wei C, Alam S, Chen X, et al
   The neurotrophic factor artemin and its receptor GFRalpha3 mediate migraine-like pain via the ion channel TRPM8.
   Cephalalgia. 2024;44:3331024241297679.
   

   >> Share

   
   

   
   Headache

4. AILANI J, Lipton RB, Blumenfeld AM, Mechtler L, et al
   Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM study.
   Headache. 2024 Nov 21. doi: 10.1111/head.14871.
   

   >> Share

   
   

   
   J Neurol Neurosurg Psychiatry

5. MAHMUD M, Kaski D
   Vestibular neurology for the generalist.
   J Neurol Neurosurg Psychiatry. 2024;95:1196-1206.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share